DelveInsight’s “Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology as well as the Nephrotic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Nephrotic Syndrome, offering comprehensive insights into the Nephrotic Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Nephrotic Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Nephrotic Syndrome therapies. Additionally, we cover the landscape of Nephrotic Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Nephrotic Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Nephrotic Syndrome space.
To Know in detail about the Nephrotic Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nephrotic Syndrome Market Forecast
Some of the key facts of the Nephrotic Syndrome Market Report:
-
The Nephrotic Syndrome market size was valued ~USD 401 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In January 2025, Hoffmann-La Roche's open-label, randomized multicenter study is designed to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared to mycophenolate mofetil (MMF) in children and young adults (ages 2 to 25) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
-
In November 2024, Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company dedicated to developing transformative treatments for serious immunological diseases, has partnered with the University of Michigan on the Nephrotic Syndrome Study Network (NEPTUNE) Match initiative. NEPTUNE is a multicenter consortium of over 30 academic institutions in North America conducting clinical and translational research on kidney diseases associated with nephrotic syndrome (NS), such as primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD). Through NEPTUNE Match, participants and their nephrologists receive tailored information about clinical trials aligned with the participant’s molecular disease profile, promoting evidence-based trial selection and improving treatment responses and outcomes.
-
In 2022, the EU4 and the UK generated an estimated USD 137 million in the Nephrotic Syndrome market, with expectations for significant growth at a strong CAGR. Germany held the largest market share among European countries in 2022, followed by the UK, France, and Italy. Spain had the smallest market share in that year.
-
In 2022, Japan accounted for around 16% of the total Nephrotic Syndrome market, with expectations for significant growth at a strong CAGR throughout the study period.
-
Key Nephrotic Syndrome Companies: GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, Vera Therapeutics, Chinook Therapeutics, Novartis, and others
-
Key Nephrotic Syndrome Therapies: Atacicept, Atrasentan, and others
-
The Nephrotic Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nephrotic Syndrome pipeline products will significantly revolutionize the Nephrotic Syndrome market dynamics.
-
It is estimated that the total number of diagnosed prevalent cases of Nephrotic Syndrome in the 7MM was around 786k in 2022, with projections indicating an increase over the forecast period.
-
In 2022, approximately 268k individuals in the United States were diagnosed with Nephrotic Syndrome, and this number is expected to grow at an estimated CAGR throughout the study period (2020–2034).
-
In the 7MM, the US represented approximately 214k cases of Primary Glomerulonephropathies and 54k cases of Secondary Glomerulonephropathies, with these numbers projected to rise during the forecast period (2023–2034).
-
In 2022, Germany had the highest number of diagnosed prevalent cases of Nephrotic Syndrome among the EU4 and the UK, with approximately 98k cases, followed by the UK and France. Conversely, Spain had the lowest diagnosed prevalent population of Nephrotic Syndrome in the EU4 and the UK.
-
In 2022, Japan reported approximately 151k diagnosed prevalent cases of Nephrotic Syndrome, with a projected decline by 2032.
Nephrotic Syndrome Overview
Nephrotic Syndrome is a kidney disorder characterized by high levels of protein in the urine, low levels of protein in the blood, swelling (edema), and high cholesterol. It occurs when the glomeruli, the filtering units of the kidneys, are damaged, allowing proteins such as albumin to leak into the urine. Common causes include diabetes, infections, and autoimmune diseases. Symptoms include swelling in the legs, face, and abdomen, along with fatigue. Treatment focuses on managing the underlying condition, reducing symptoms, and preventing complications.
Get a Free sample for the Nephrotic Syndrome Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
Nephrotic Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Nephrotic Syndrome Epidemiology Segmentation:
The Nephrotic Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Nephrotic Syndrome
-
Prevalent Cases of Nephrotic Syndrome by severity
-
Gender-specific Prevalence of Nephrotic Syndrome
-
Diagnosed Cases of Episodic and Chronic Nephrotic Syndrome
Download the report to understand which factors are driving Nephrotic Syndrome epidemiology trends @ Nephrotic Syndrome Epidemiology Forecast
Nephrotic Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nephrotic Syndrome market or expected to get launched during the study period. The analysis covers Nephrotic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Nephrotic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Nephrotic Syndrome Therapies and Key Companies
-
Atacicept: Vera Therapeutics
-
Atrasentan: Chinook Therapeutics/ Novartis
Discover more about therapies set to grab major Nephrotic Syndrome market share @ Nephrotic Syndrome Treatment Landscape
Nephrotic Syndrome Market Drivers
-
Advancements in Treatment Options
-
Rising Disease Awareness
-
Improved Diagnostic Tools
-
Supportive Healthcare Policies
-
Growing Prevalence of Risk Factors
-
Focus on Pediatric Research
Nephrotic Syndrome Market Barriers
-
High Treatment Costs
-
Limited Awareness in Low-income Regions
-
Side Effects of Current Therapies
-
Complex Disease Pathophysiology
-
Scarcity of Large-scale Clinical Trials
-
Regulatory Challenges
Scope of the Nephrotic Syndrome Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Nephrotic Syndrome Companies: GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, Vera Therapeutics, Chinook Therapeutics, Novartis, and others
-
Key Nephrotic Syndrome Therapies: Atacicept, Atrasentan, and others
-
Nephrotic Syndrome Therapeutic Assessment: Nephrotic Syndrome current marketed and Nephrotic Syndrome emerging therapies
-
Nephrotic Syndrome Market Dynamics: Nephrotic Syndrome market drivers and Nephrotic Syndrome market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Nephrotic Syndrome Unmet Needs, KOL’s views, Analyst’s views, Nephrotic Syndrome Market Access and Reimbursement
To know more about Nephrotic Syndrome companies working in the treatment market, visit @ Nephrotic Syndrome Clinical Trials and Therapeutic Assessment
Table of Contents
1. Nephrotic Syndrome Market Report Introduction
2. Executive Summary for Nephrotic Syndrome
3. SWOT analysis of Nephrotic Syndrome
4. Nephrotic Syndrome Patient Share (%) Overview at a Glance
5. Nephrotic Syndrome Market Overview at a Glance
6. Nephrotic Syndrome Disease Background and Overview
7. Nephrotic Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Nephrotic Syndrome
9. Nephrotic Syndrome Current Treatment and Medical Practices
10. Nephrotic Syndrome Unmet Needs
11. Nephrotic Syndrome Emerging Therapies
12. Nephrotic Syndrome Market Outlook
13. Country-Wise Nephrotic Syndrome Market Analysis (2020–2034)
14. Nephrotic Syndrome Market Access and Reimbursement of Therapies
15. Nephrotic Syndrome Market Drivers
16. Nephrotic Syndrome Market Barriers
17. Nephrotic Syndrome Appendix
18. Nephrotic Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
